Takeda settles six Actos patent suits
OSAKA, Japan Japanese drug maker Takeda has settled with 6-of-the-8 generic drug companies that it had filed patent infringement suits against over their attempts to market versions of two diabetes drugs, Takeda said Wednesday.
Takeda and its U.S. division said it still had pending patent infringement suits against Israel’s Teva Pharmaceutical Industries and India’s Aurobindo Pharma concerning the drugs Actos (pioglitazone hydrochloride) and Actoplus met (pioglitazone hydrochloride and metformin hydrochloride). Takeda said it expected generic versions of the drugs to enter the market in August and December 2012, respectively, under licensing agreements. The patents for the drugs expire in 2016.
The six companies with which Takeda has settled are Mylan, Watson Pharmaceuticals, Ranbaxy Labs, Alphapharm, Torrent Pharmaceuticals and Sandoz. As the first companies to file for regulatory approval and challenge Takeda’s patents for Actos, they will each have six months’ market exclusivity in which to compete directly with Takeda once they launch in August 2012; Mylan will launch its version of Actoplus met in December 2012.
NACDS Foundation elects new board members
ALEXANDRIA, Va. The charitable arm of the National Association of Chain Drug Stores has appointed seven new members to its board of directors.
New members of the NACDS Foundation each will serve one-year term, the organization said. Newly elected NACDS Foundation board members include:
- Joseph W. Cavaliere, SVP customer development of Unilever;
- Debbie B. Garza, divisional VP government and community relations at Walgreens;
- William Graham, VP sales at Beiersdorf;
- David Klaum, general manager of Fougera and Nycomed US SVP;
- Louis J. Martire, VP trade development of Energizer Holdings;
- David A. Moules, VP channel development, patient assistance and reimbursement programs of GlaxoSmithKline; and,
- Robert Potter, SVP sales and marketing of Mylan Pharmaceuticals.
“The NACDS Foundation is dedicated to improving and advancing public health and wellness,” said NACDS Foundation president Edith A. Rosato. “Our board, which is truly representative of the pharmacy community –– from retailers and pharmaceutical companies to consumer product businesses –– shares in our commitment to education, research and charity. I applaud the pharmacy community’s support of the Foundation, welcome our new Board members, and look forward to working with them to implement the foundation’s vision and mission.”
Judge upholds patent for Protonix DR
JERUSALEM The U.S. District Court for the District of New Jersey has ruled that a patent covering a drug for gastroesophageal reflux disease is valid, Teva said.
A jury found that U.S. Patent No. 4,758,579, covering the drug Protonix DR (pantoprazole sodium) was valid, though a decision by the District Court judge independent of the jury’s verdict could still invalidate it.
Wyeth marketed the drug before its acquisition by Pfizer last year. Teva began shipping its generic version in December 2007.